British American Tobacco PLC ADR BTI
|
|
|
- Alaina Booker
- 6 years ago
- Views:
Transcription
1 Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ [ % $ bil 594, mil Stock Price XNYS:BTI: % 2018 Morningstar s Take The advent of e-cigarettes has created the most significant change in the industry since the 1960s. Early forms of e-cigarettes have existed for a generation, but with the consumer... Key Stats Stock Ind Avg Price/Earnings TTM Price/Book Price/Sales TTM Rev Growth (3 Yr Avg) Net Income Growth (3 Yr Avg) Operating Margin % TTM Net Margin % TTM ROA TTM ROE TTM Debt/Equity Financials Fair Value Estimate $ Consider Buying $ Consider Selling $ Fair Value Uncertainty Low Economic Moat Wide Stewardship Standard Growth V Profitability Z Morningstar Credit Rating Relative to Industry - Avg + Annual Quarterly Income Statement Revenue 14,751 13,104 13,971 Operating Income 4,655 4,557 4,546 Net Income 4,648 4,290 3,115 Earnings Per Share Shares Outstanding 1,865 1,863 1,870 Dividends Declared Date 05/12/2017 Ex-Dividend Date 28/12/2017 Latest Indicated Dividend Amount 0.59 Projected Yield 1.64 % Recent Dividends & Type Amount Splits 12/28/2017 Cash Dividends /16/2017 Cash Dividends /15/2017 Cash Dividends /14/2017 Split 2:1 Competitors Name Price % Chg TTM Sales $ mil British American $ [ 22,147 Tobacco PLC ADR Philip Morris International Inc $ ] 27,425 British American Tobacco PLC $ ] 22,147 Altria Group Inc $ [ 19,513 Japan Tobacco Inc $ ] 19,191 Japan Tobacco Inc ADR $ ] 19,191 Recommendations Current 4.3 Total Analysts: Buy Hold Sell Ownership Fund Owners Star Rating % Shares Held % Total Assets Scotia Diversified MonthlyQQQ Income Adv Imperial Global Equity Income Pool Dynamic Strategic Yield QQ Ser FI Horizons Active Global Dividend ETF Comm QQQQ Guardian Global Dividend QQ Growth Series W Balance Sheet Current Assets 12,359 9,814 9,132 11,474 10,689 Non Current Assets 27,414 21,701 17,035 27,712 25,550 Total Assets 39,773 31,515 26,167 39,186 36,239 Current Liabilities 11,856 9,006 8,769 13,196 11,787 Total Liabilities 31,591 20,657 31,469 30,129 Stockholders' Equity 8,182 4,894 5,510 7,717 6,110 Cash Flow Cash From Operations 4,610 4,720 3,716 1,706 1,054 Capital Expenditures
2 Morningstar Analyst Rating. Page 2 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ [ % $ bil 594, mil Financials Annual Quarterly Free Cash Flow 3,936 4,119 3,024 1, In millions except "EPS". Currency in GBP.
3 Page 3 of 5 Industry Classification NAICS () SIC ISIC Manufacture of Tobacco Products (1200) Operation Details Fiscal Year Ends CIK Year Established Employees (31/12/2016) Full Time Part Time Auditor (15/10/2015) KPMG Legal Advisor (26/04/2013) Baker & McKenzie LLP Key Executives Nicola Snook/Company Secretary; Neil R Withington/Group Legal and Security Director and General Counsel; Giovanni Giordano/Group Human Resources Director; Ben Stevens/Finance Director, Chief Information Officer and Director; Alan Davy/Group Operations Director; Des Naughton/Managing Director, Next Generation Products; Ricardo Oberlander/Director, Americas; Kingsley Wheaton/Deputy Corporate and Regulatory Affairs Director; Jack Bowles/Director, Asia-Pacific; David O'reilly/Group Scientific Director; Naresh Sethi/Director, Western Europe; Jean Marc Levy/Group Marketing Director; Nicandro Durante/Chief Executive Officer and Director; Andrew Gray/Director, Eastern Europe, Middle East and Africa Company Profile British American Tobacco PLC manufactures and sells cigarettes and other tobacco products under the brands Dunhill, Kent, Lucky Strike, Pall Mall and Rothmans. It also offers Vapour Products, like e-cigarettes, and Tobacco Heating Products. 30-day Avg Volume Market Cap Net Income Sales Sector Industry Stock Style Direct Investment Dividend Reinvestment 1.6Mil 163.5Bil 5.9Bil 22.1Bil Consumer Defensive Tobacco 7 Large Growth No No
4 Page 4 of 5 Industry Peers Morningstar Rating Market Cap $Mil Net Income $Mil P/S P/B P/E Dividend Yield% 5 Yr Rev CAGR% Med Oper. Margin% Interest Coverage British American Tobacco PLC (GBP) QQ 163,543 4, Philip Morris International Inc (USD) QQ 170,122 7, British American Tobacco PLC (USD,GBP) 163,543 4, Altria Group Inc (USD) QQ 136,340 15, Japan Tobacco Inc (USD,JPY) 59, , Japan Tobacco Inc (USD,JPY) 59, , Hanjaya Mandala Sampoerna Tbk (USD,IDR) 47,917 13,018, , Imperial Brands PLC (USD,GBP) QQQQ 39,749 1, Imperial Brands PLC (USD,GBP) 39,749 1, Perusahaan Rokok Tjap Gudang Garam Tbk (USD,IDR) 12,278 7,493, Swedish Match AB (USD,SEK) 7,485 3, Swedish Match AB (USD,SEK) 7,485 3, Vector Group Ltd (USD) 2, British American Tobacco Malaysia Bhd (USD,MYR) 2, Scandinavian Tobacco Group A/S (USD,DKK) 1, Universal Corp (USD) 1, Turning Point Brands Inc (USD) Vapetek Inc (USD) , Alliance One International Inc (USD) mcig Inc (USD) Gilla Inc (USD) Vapir Enterprises Inc (USD) Bang Holdings Corp (USD) , Avalanche International Corp (USD) , Vapor Group Inc (USD) VPR Brands LP (USD) ,323.7 Vape Holdings Inc (USD) Healthier Choices Management Corp (USD) Electronic Cigarettes International Group Ltd (USD) Intercontinental Technology Inc (USD) ,021.1 Nhale Inc (USD) Bellatora Inc 0 Vapor Hub International Inc (USD) ML Capital Group Inc (USD) , Philip Morris CR AS (USD,CZK) 3, Perusahaan Rokok Tjap Gudang Garam Tbk (USD,IDR) 7,493, KT&G Corp (USD,KRW) 1,228, American Heritage International Inc (USD) ,406.7 Scandinavian Tobacco Group A/S (USD,DKK) Smokefree Innotec Inc Green and Hill Industries Inc (USD) 0-277,854.7 El Maniel International Inc (USD) 0-1,269.2 Karelia Tobacco Co Inc SA (USD,EUR) A1 Group Inc (USD) KT&G Corp (USD,KRW) 1,228, Wee-Cig International Corp (USD) -1-5,195.3 ITC Ltd (USD,INR) 102, Icon Vapor Inc (USD) , VaporBrands International Inc (USD) Swan Group of Companies Inc D/E
5 Page 5 of 5 Industry Peers Industry Average 26, , ,
Altria Group Inc. Ticker: MO
Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Morningstar Analyst Rating Page 1 of 7 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 34.37 [-0.26-0.75 % $ 34.78 34.30-34.94
Q Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
Q2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
Q Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
Q Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
Q Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
Q Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
Vontobel Viewpoints FDA New Direction on Tobacco Our Take
Quality Growth Boutique TM Vontobel Viewpoints On July 28, 2017, the new Commissioner of the U.S. Food and Drug Administration (FDA), Scott Gottlieb, surprised the markets by launching a consultation paper
1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
Altria Group Inc (MO-NYSE)
March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $54.00
For personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
WntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
(LO-NYSE) SUMMARY. Risk Level *
February 12, 2015 Lorillard Inc. (LO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 05/22/2012 Current Price (02/11/15) $67.55 Target Price $71.00
Korean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
Global E-Cigarette Market- Industry Analysis & Outlook ( )
Global E-Cigarette Market- Industry Analysis & Outlook (2016-2020) ----------------------------------------- Executive Summary Electronic cigarettes, also known as E-cigarettes, electronic nicotine delivery
Tobacco Insights May
Tobacco Insights 2015 - May Product Code: TI0017MR Published Date: June 2015 Report Price: US$ 150 (Single Copy) Synopsis Tobacco Insights 2015 - May report is a qualitative report providing extensive
22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
Consolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
Corcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
Forward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
WntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in
Endesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
HILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
Slide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
Global E-Cigarette & Vaporizer Market Research Report - Forecast to 2027
Report Information More information from: https://www.marketresearchfuture.com/reports/788 Global E-Cigarette & Vaporizer Market Research Report - Forecast to 2027 Report / Search Code: MRFR/CR/0304-CRR
MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
FIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
Summary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06
VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC
XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
Orexigen Therapeutics, Inc.
February 27, 2015 Orexigen Therapeutics, Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 06/06/2012 Current Price (02/26/15) $5.87 Target Price $6.25 SUMMARY DATA
1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
Medivation, Inc. (MDVN-NASDAQ)
March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY
DELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
Coloplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
THE GLOBAL TOBACCO ECONOMY
Future Options for Tobacco Control THE GLOBAL TOBACCO ECONOMY A SNAPSHOT OF THE ECONOMIES OF MULTINATIONAL TOBACCO COMPANIES AND OF INTERNATIONAL TOBACCO CONTROL EFFORTS IN 2008. September 2009 Physicians
Zacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018 Árpád Könye Chairman of the Board of Directors Total Cigarette Market Czech Republic Total cigarette market down
Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
Q Investor Kit January December 2015
Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local
ELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
Investor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
Shareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
PROACTIVE INVESTOR PRESENTATION
www.thcl.com.au ASX RELEASE (16 th May 2017) PROACTIVE INVESTOR PRESENTATION The Hydroponics Company Limited (ASX: THC) is pleased to advise that Dr Andrew Beehag, Chief Executive Officer of Canndeo Limited,
Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
Welcome to the Full -Year Results Press Conference
Welcome to the Full -Year Results Press Conference Disclamer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements
Fund Performance Bulletin
Fund Performance Bulletin March 2, 200 March 2, 200 Page of 0 PATHFINDER B20 Hansard Pathfinder UK 29/0/99..444.97.. -2.4.77 27.00.0 2.82 C20 Hansard Pathfinder America /2/98.0. 4. 7.9 7. -20.44-4.89-2.42
Fund Performance Bulletin
Fund Performance Bulletin April 29, 200 April 29, 200 Page of s s s 0 s PATHFINDER B20 Hansard Pathfinder UK 29/0/99..44 -.84 7.40 27. -4.2 9.29.20.0 2.80 C20 Hansard Pathfinder America /2/98.07.2 2.28.7.20-2.9-0.4-2.94
Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
NOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers
NOVO NORDISK Analyst: Recommendation: HOLD DATE: 11.11.2015 Industry: Drug manufacturers Share price 375,00 DKK Homepage www.novonordisk.com Ticker NVO Number of shares (000) 2.563.800 Target price 406,14
International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
Investor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
22nd Century Group, Inc. (XXII - $ Buy)
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
Letter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
Investor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
Walgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
Coloplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
Introductory Presentation
Introductory Presentation WEEK 6 WEEK WEEK 1 2 WEEK 5 WEEK 3-4 STRUCTURED HORIZON WELCOME TO THE FAMILY FRANCHISE AGREEMENT DELIVERY PERSONALIZED FRANCHISE AGREEMENTS DELIVERED DAY OF DISCOVERY MEET THE
Third-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
Perrigo Company plc (PRGO-NYSE)
March 20, 2015 Perrigo Company plc (PRGO-NYSE) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 09/02/2012 Current Price (03/19/15) $170.37 Target Price $179.00 SUMMARY
RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance
Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance
CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
SWEDISH MATCH RESULTS PRESENTATION Q4 2018
SWEDISH MATCH RESULTS PRESENTATION Q4 2018 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,
Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
Small-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
FY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
Fund Performance Bulletin
Fund Performance Bulletin July 7, 2009 July 7, 2009 Page of 0 PATHFINDER B20 Hansard Pathfinder UK 29/0/99.072.8-2.99 -.42-4.8-20.77 2.8 N/A 7.20 0.72 C20 Hansard Pathfinder America /2/98 0.849 0.97-4.0
Forward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
Financial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
RUBBER GLOVES. Rationale for report : Sector update
Investment Highlights RUBBER GLOVES RUBBER PRODUCTS Ebola - the latest health scare 5 August 2014 NEUTRAL Cheryl Tan cheryl-tan@ambankgroup.com +603 2036 2333 Rationale for report : Sector update (Maintained)
A world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
PRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
Small-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK
Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:
SWEDISH MATCH RESULTS PRESENTATION Q3 2017
SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,
For personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
A GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
MDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More information at
Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User
Singapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
Fund Performance Bulletin
Fund Performance Bulletin September 22, 2009 September 22, 2009 Page of 0 PATHFINDER B20 Hansard Pathfinder UK 29/0/99.2.. 27..9-8.4 7.82 N/A 2.0 2.9 C20 Hansard Pathfinder America /2/98 0.974.02.8 2.24-2.
Results Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
Novo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store
Actual Store Low Price & Great Value $5,6, 6.% CAP Rate Open & paying rent--available for immediate sale Lower price point and great value Offered free & clear; loans available today with as little as
Philip Morris International (PMI)
Philip Morris International (PMI) Philip Morris International Inc. (PMI) became a separate legal entity from Altria in March 2008. PMI is a Virginia corporation with headquarters in New York. PMI only
Imperial Brands Maximising Category Opportunities CAGNY February 2019
Imperial Brands Maximising Category Opportunities CAGNY 2019 21 February 2019 Disclaimer Certain statements in this announcement constitute or may constitute forward-looking statements. Any statement in
Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )
Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,
Small-Cap Research. Delmar Pharma (DMPI-OTCQB)
Small-Cap Research February 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Ready to advance VAL-083 to pivotal